Literature DB >> 83302

Characterization of the cross-reaction between type 19F(19) and 19A(57) pneumococcal capsular polysaccharides: compositional analysis and immunological relation determined with rabbit typing antisera.

T Krishnamurthy, C J Lee, J Henrichsen, D J Carlo, T M Stoudt, J B Robbins.   

Abstract

The immunological relation, physicochemical characteristics, and chemical composition of type 19F(19) and 19A(57) within the cross-reactive group 19 pneumococcal capsular polysaccharides were studied. By using rabbit hyperimmune diagnostic antisera in agglutination, immunodiffusion, quantitative precipitation, and absorption assays, extensive cross-antigenicity and cross-immunogenicity were demonstrable between the disease-associated types 19F(19) and 19A(57). Types 19B(58) and 19C(59), rarely associated with human disease, were extensively cross-reactive with each other but reacted weakly with types 19F(19) and 19A(57). Both types 19F(19) and 19A(57) polysaccharides contained trace amounts of protein and nucleic acid and had comparable molecular sizes as determined by gel filtration. Compositional analysis showed type 19F(19) to contain rhamnose, glucose, N-acetylmannosamine, and a phosphate ester. Type 19A(57) contained these four moieties, and in addition, contained fucose, galactose, and N-acetylglucosamine. Plans for using this information to evaluate current and proposed formulation of multivalent pneumococcal polysaccharide vaccines are discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 83302      PMCID: PMC422220          DOI: 10.1128/iai.22.3.727-735.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  The quellung reaction, a neglected microbiologic technique.

Authors:  R Austrian
Journal:  Mt Sinai J Med       Date:  1976 Nov-Dec

2.  Rapid diagnosis of sickle cell disease at birth by microcolumn chromatography.

Authors:  D Powars; W A Schroeder; L White
Journal:  Pediatrics       Date:  1975-05       Impact factor: 7.124

3.  The bacteriology of pneumococcal otitis media.

Authors:  R Austrian; V M Howie; J H Ploussard
Journal:  Johns Hopkins Med J       Date:  1977-09

4.  Primary structure of streptococcal proteinase. I Isolation, composition, and amino acid sequences of the tryptic and chymotryptic peptides of cyanogen bromide fragments 1 to 4.

Authors:  A A Kortt; R J Wysocki; T Y Liu
Journal:  J Biol Chem       Date:  1976-04-10       Impact factor: 5.157

5.  Antigenic relationship between pneumococci and non-hemolytic streptococci.

Authors:  E LUND
Journal:  Acta Pathol Microbiol Scand       Date:  1950

Review 6.  Serology, chemistry, and genetics of O and K antigens of Escherichia coli.

Authors:  I Orskov; F Orskov; B Jann; K Jann
Journal:  Bacteriol Rev       Date:  1977-09

7.  The type-specific substance from Pneumococcus type 10A(34). Structure of the dephosphorylated repeating unit.

Authors:  E V Rao; J G Buchanan; J Baddiley
Journal:  Biochem J       Date:  1966-09       Impact factor: 3.857

8.  Latex agglutination test for the diagnosis of Haemophilus influenzae meningitis.

Authors:  R B Newman; R W Stevens; H A Gaafar
Journal:  J Lab Clin Med       Date:  1970-07

9.  Changes in occurrence of capsular serotypes of Streptococcus pneumoniae at Boston City Hospital during selected years between 1935 and 1974.

Authors:  M Finland; M W Barnes
Journal:  J Clin Microbiol       Date:  1977-02       Impact factor: 5.948

10.  Streptococcus pneumoniae resistant to penicillin and chloramphenicol.

Authors:  P C Appelbaum; A Bhamjee; J N Scragg; A F Hallett; A J Bowen; R C Cooper
Journal:  Lancet       Date:  1977-11-12       Impact factor: 79.321

View more
  10 in total

1.  Improving Scientific Research and Writing Skills through Peer Review and Empirical Group Learning.

Authors:  Emilee Senkevitch; Ann C Smith; Gili Marbach-Ad; Wenxia Song
Journal:  J Microbiol Biol Educ       Date:  2011-12-01

2.  Cross-immunogenicity of pneumococcal group 9 capsular polysaccharides in adult volunteers.

Authors:  S C Szu; C J Lee; J C Parke; G Schiffman; J Henrichsen; R Austrian; S C Rastogi; J B Robbins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

3.  Pneumococcal serotypes causing bacteremia and meningitis: relevance to composition of pneumococcal vaccine.

Authors:  J M Dixon; A E Lipinski
Journal:  Can Med Assoc J       Date:  1981-08-01       Impact factor: 8.262

4.  Antibody responses in adult volunteers to pneumococcal polysaccharide types 19F and 19A administered singly and in combination.

Authors:  R L Penn; E B Lewin; R G Douglas; G Schiffman; C J Lee; J B Robbins
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

5.  Maternal immunity and antibody response of neonatal mice to pneumococcal type 19F polysaccharide.

Authors:  C J Lee; E D Ching; J H Vickers
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

6.  Comparative immunogenicity of group 6 pneumococcal type 6A(6) and type 6B(26) capsular polysaccharides.

Authors:  J B Robbins; C J Lee; S C Rastogi; G Schiffman; J Henrichsen
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

7.  Maternal-foetal interaction, antibody formation, and metabolic response in mice immunized with pneumococcal polysacharides.

Authors:  C J Lee
Journal:  Immunology       Date:  1980-09       Impact factor: 7.397

8.  Immunochemical characterization of cross-reactivity of pneumococcal group 9 capsular polysaccharide types 9N, 9A, 9L, and 9V.

Authors:  S Szu; C J Lee; D Carlo; J Henrichsen
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

9.  Immune response of neonates to pneumococcal polysaccharide-protein conjugate.

Authors:  K T Lin; C J Lee
Journal:  Immunology       Date:  1982-06       Impact factor: 7.397

10.  Ultrastructural localization of capsules, cell wall polysaccharide, cell wall proteins, and F antigen in pneumococci.

Authors:  U B Skov Sørensen; J Blom; A Birch-Andersen; J Henrichsen
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.